Acquired Company
Eliem Therapeutics acquired Tenet Medicines on June 27, 2024, with pre‑acquisition Tenet equityholders expected to own approximately 15% and pre‑acquisition Eliem equityholders approximately 85% of the combined company after the close and concurrent private placement.
Show more
Start AI Chat
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$5.27
Open
$5.63
Volume
1,054,663
Day Range
$5.56 - $6.22
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Budoprutug Details Kidney disease, Primary Membranous Nephropathy | Phase 1b Update | |
ETX-155 Details Epilepsy | Failed Discontinued | |
ETX-810 Details Chronic pain, Pain, Sciatica | Failed Discontinued | |
ETX-155 Details Major depressive disorder, Perimenopausal Depression | Failed Discontinued | |
ETX-810 Details Chronic pain, Sciatica , Pain, Diabetes | Failed Discontinued | |
ETX-123 (Kv7.2/3 channel opener) Details Epilepsy, Seizures, Pain | Failed Discontinued |
